Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 Months of retreatment and vision outcomes from a randomized study

Ophthalmologica

Volumn 233, Issue 2, 2015, Pages 66-73

  Hatz, Katja ^a,b,c   Schneider, Ulrike ^c   Henrich, P Bernhard ^c   Braun, Beatrice ^c   Sacu, Stefan ^d   Prünte, Christian ^a,b,c,d  

^a Vista Klinik   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Age related macular degeneration; Anti VEGF; Photodynamic therapy

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MALE; MONOTHERAPY; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA NEOVASCULARIZATION; RETREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETREATMENT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84924242166     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000367603     Document Type: Article

References (25)

1. Schmidt-Erfurth U, Hasan T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195-214.
2. Bressler NM: Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
3. Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
4. Augustin AJ, Schmidt-Erfurth U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 14-22.
5. Ozkiris A: Anti-VEGF agents for age-related macular degeneration. Expert Opin Ther Pat 2010; 20: 103-118.
6. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G; SUSTAIN Study Group: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-671.
7. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
8. Kaiser PK: Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007; 23: 477-487.
9. Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Luke M, Bartz-Schmidt KU, Grisanti S: Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006; 142: 95-104.
10. Lazic R, Gabric N: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to agerelated macular degeneration. Ophthalmology 2007; 114: 1179-1185.
11. Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC: A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010; 24: 1561-1567.
12. Giustolisi R, Fantozzi N, Staltari M, Marchiori J, Mastrangelo O, Marcucci R, Mirra F, Mazzotta P, Gabrieli CB: Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration. Digit J Ophthalmol 2011; 17: 23-30.
13. Bashshur ZF, Schakal AR, El Mollayess GM, Arafat S, Jaafar D Salti HI: Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with asneeded ranibizumab treatment for the management of neovascular age-related macular degeneration. Retina 2011; 31: 636-644.
14. Krebs I, Vecsei Marlovits V, Bodenstorfer J, Glittenberg C, Ansari Shahrezaei S, Ristl R, Binder S: Comparison of ranibizumab monotherapy versus combination of ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmol 2013; 91:e178-e183.
15. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A; DENALI Study Group: Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012; 119: 1001-1010.
16. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A; MONT BLANC Study Group: Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012; 119: 992-1000.
17. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-4480.
18. Novartis Europharm Ltd: Lucentis ® (ranibizumab) Summary of Product Characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000715/WC500043546. pdf (accessed April 15, 2013).
19. Holm S: A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65-70.
20. Zhang J, Quan H, Ng J, Stepanavage ME: Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials 1997; 18: 204-221.
21. Dewi NA, Yuzawa M, Tochigi K, Kawamura A, Mori R: Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area. Jpn J Ophthalmol 2008; 52: 277-281.
22. Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, Wolf S: Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. Acta Ophthalmol 2011; 89: 585-590.
23. Sacu S, Varga A, Michels S, Weigert G, Polak K, Vecsei-Marlovits PV, Schmidt-Erfurth U: Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. Br J Ophthalmol 2008; 92: 1347-1351.
24. Chen E, Brown DM, Wong TP, Benz MS, Kegley E, Cox J, Fish RH, Kim RY: Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol 2010; 4: 1073-1079.
25. Cruess AF, Zlateva G, Pleil AM, Wirostko B: Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol 2009; 87: 118-132.